A Phase I Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6002 in Healthy Adult Volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2014
At a glance
- Drugs AVI 6002 (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 16 Oct 2014 Results published in the November 2014 issue of the journal Antimicrobial Agents and Chemotherapy, according to a Sarepta Therapeutics media release.
- 16 Oct 2014 Results published in a Sarepta Therapeutics media release.
- 03 Apr 2012 Results were presented at the 22nd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).